Phase two clinical trial of limited stage lymphoblastic lymphoma.

JRCT ID: jRCTs041180131

Registered date:26/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Limited stage lymphoblastic lymphoma
• Date of first enrollment: 26/03/2019
• Target sample size: 48
• Study type: Interventional
• Intervention(s): Treatment regimen has fundamentally BFM backbone with reinduction phase

Outcome(s)

• Primary Outcome: 3 year event-free survival

Secondary Outcome

(1) 3year overall survival
(2)Incidence of therapy-rerated severe toxicity

Key inclusion & exclusion criteria

• Age minimum: >=
• Age maximum: < 18age old
• Gender: Both
• Include criteria: Newly diagnosed patients with limited T and B cell lymphoblastic lymphoma

Exclude criteria

1, Down's syndrome
2, previous malignancy of any type
3, Prior stem cell or organ transplantation
4, Congenital or acquired immunodeficiency

Related Information

• Primary Sponsor: Sekimizu Masahiro
• Source(s) of Monetary Support: Ministry of Health, Labour and Welfare,Japan Agency for Medical Research and Development
• Secondary ID(s): UMIN000002213